



At Gilead, our vision is to create a healthier world by delivering innovative medicines that aim to prevent, treat and cure life-threatening diseases. We pursue advancements in science with the goal of improving care in areas of unmet medical need – setting out to make the impossible possible.

HIV

Gilead has been a leader of care for people living with HIV, including developing single tablet regimens to treat HIV and medicines to help prevent HIV. We have made significant strides progressing our investigational long-acting antiviral, and our scientists continue to search for a potential cure.

ONCOLOGY

Today, our oncology programs are at various stages of development – from clinical candidates in solid tumors and hematological malignancies to our marketed product for metastatic triple-negative breast cancer and bladder cancer. And with our colleagues at Kite, we are driving advances in cell therapy.

VIRAL HEPATITIS

Gilead has delivered four curative hepatitis C virus therapies in less than four years; we are also providing options for people with hepatitis B virus as we pursue a cure.



Our decades of antiviral expertise allowed us to contribute to when the COVID-19 outbreak began. Our scientists began to examine the potential of our then-investigational antiviral which had shown potential against other viral pathogens including Ebola, SARS and MERS. We remain committed to supporting the global community in overcoming the pandemic.



**ESTABLISHED IN
2011 AND OVER 300
EMPLOYEES IN ASIA 5**



LEADING RESEARCH AND DEVELOPMENT IN ASIA

ADDRESSING UNMET MEDICAL NEEDS

>90
Investigator
Sponsored
Research

>50
Clinical Trials
Across Asia

Gilead continues to prioritize collaboration in pursuit of scientific innovation through

- Conquering hepatitis via medical research grants and partnerships
- Gilead Sciences Research Scholars Program in HIV and liver disease in Asia
- Launch of HIV.ASIA and LIVER.ASIA
- Open innovation collaborations for NASH in Korea



INCLUSION AND DIVERSITY AT GILEAD ASIA

We are committed to creating an inclusive culture that enables all people to do their best work and that reflects the diversity of the people, patients and communities we serve.

INCLUSIVE LEADERSHIP JOURNEY

Since 2019, we have enhanced inclusion and diversity training, created specialized development experiences for our diverse employees and increased our focus on attracting, developing and retaining people of diverse backgrounds.

EMPLOYEE RESOURCE GROUPS

Our employee resource groups, like Pride Alliance and Women at Gilead, are open to employees to foster a sense of belonging that can spark innovation and accelerate employee development.



A PARTNER OF CHOICE

Through collaboration with community groups and local partners, we are committed to supporting UNAIDS' goal to end the HIV epidemic by 2030, as well as the World Health Organization's target to eliminate viral hepatitis as a public health threat by 2030.



CREATING POSSIBLE FOR OUR COMMUNITIES

In 2020, we provided more than US\$500,000 of financial and resource support to charities in response to unprecedented challenges facing some of the hardest hit communities due to COVID-19. Donations provided basic necessities to low-income families, including education resources to children, care kits to the homeless and vulnerable families across Asia.



ENDING THE HIV EPIDEMIC IN ASIA

Since 2018, we have partnered with local health authorities, NGOs and academic institutions to support HIV prevention for key populations in Taiwan, Hong Kong and Korea through donations and research projects. Data collected have helped develop effective local HIV prevention strategies.



MICRO-ELIMINATION OF HCV IN TAIWAN

We collaborated with Taiwan's Ministry of Health and Welfare in a pilot micro-elimination project that provided 1,000 patients in indigenous towns access to free oral antiviral treatment.



ASIA PACIFIC RAINBOW GRANT

The Asia Pacific Rainbow Grant aims to support projects that engage the communities affected by HIV and AIDS across Asia. The program impacts 23 markets across Asia Pacific, and has awarded over US\$4.5 million to more than 122 projects that range from disease education to digital engagement, fighting stigma and capacity building.



ALL4LIVER ASIA PACIFIC GRANT

Inspired by the Gilead Liver Index study (2020), the ALL4LIVER Asia Pacific Grant aims to empower organizations to raise awareness on hepatitis B and bring liver health to the forefront. More than US\$1 million has been granted to community-led projects across 11 territories in Asia Pacific that help strengthen liver disease education.

ACCOLADES IN ASIA



Ranked #1 pharma company for supporting Asian patients and patient groups during COVID-19 by PatientView 2020 excelling in best high-quality patient information, transparency, integrity and providing services



Only pharma company to receive the 2021 Taiwan Sustainability Action Award in recognition of contributions to the 2020 Pride Parade Campaign to advance the fifth SDG on Gender Equality



Listed in the 2021 Hong Kong LGBT+ Inclusion Index as the first healthcare company to be included in the index



Received the Top Ten Enterprise of the Year at the 15th Golden Torch Awards in Taiwan from the Outstanding Enterprise Manager Association



Received the International Innovation Award at the 16th and 17th National Innovation Awards in Taiwan by the Research Center for Biotechnology and Medicine Policy



Awarded the Chosun BizSocial Contribution Award 2019 in Korea by the Korean Ministry of Health and Welfare